Assenagon Asset Management
MRNA icon

Assenagon Asset Management’s Moderna MRNA Stock Holding History

Assenagon Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,623
Closed -$471K – 1206
2025
Q1 		$471K Buy
16,623
+1,645
+11% +$58.4K ﹤0.01% 1025
2024
Q4 		$623K Buy
14,978
+1,819
+14% +$86.9K ﹤0.01% 1170
2024
Q3 		$879K Buy
13,159
+5,807
+79% +$533K ﹤0.01% 1156
2024
Q2 		$873K Buy
7,352
+843
+13% +$107K ﹤0.01% 1130
2024
Q1 		$694K Buy
6,509
+530
+9% +$53.4K ﹤0.01% 1137
2023
Q4 		$595K Sell
5,979
-1,083
-15% -$91.1K ﹤0.01% 1226
2023
Q3 		$729K Buy
7,062
+260
+4% +$29K ﹤0.01% 1123
2023
Q2 		$826K Sell
6,802
-1,318
-16% -$176K ﹤0.01% 1016
2023
Q1 		$1.25M Sell
8,120
-736
-8% -$121K ﹤0.01% 976
2022
Q4 		$1.59M Buy
8,856
+1,075
+14% +$176K 0.01% 893
2022
Q3 		$920K Buy
7,781
+5,533
+246% +$840K ﹤0.01% 946
2022
Q2 		$321K Sell
2,248
-803
-26% -$115K ﹤0.01% 1314
2022
Q1 		$526K Buy
3,051
+350
+13% +$58.9K ﹤0.01% 1199
2021
Q4 		$686K Sell
2,701
-226
-8% -$66.1K ﹤0.01% 1137
2021
Q3 		$1.13M Buy
+2,927
New +$1.08M ﹤0.01% 869

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Assenagon Asset Management's MRNA Position: Q2 2025 in Review

Assenagon Asset Management sold out of Moderna (MRNA) in Q2 2025, closing a stake of 16,623 shares — an estimated $471K sold.

Assenagon Asset Management first reported a position in MRNA in Q3 2021 and held it in 15 quarters. The position peaked at $1.59M in Q4 2022. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Assenagon Asset Management reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 16,623 Moderna shares in Q2 2025, an estimated $471K.
  • Assenagon Asset Management first reported a position in Moderna in Q3 2021 and held it in 15 quarters.
  • Assenagon Asset Management's Moderna position peaked at $1.59M in Q4 2022.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Assenagon Asset Management's 13F filing for Q2 2025, filed 11 Jul 2025.